Imagion CEO Bob Proulx discusses the company’s path to first-in-human trials plus early discussions with potential partners and strategic investors in this Margermarket article.
Read the article.
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
December 7, 2023
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited